Synairgen plc Synairgen Presents SNG001 Data at ESWI (5997U)
06 Diciembre 2021 - 1:00AM
UK Regulatory
TIDMSNG
RNS Number : 5997U
Synairgen plc
06 December 2021
Press Release
Synairgen plc
('Synairgen' or the 'Company')
Synairgen to Present Clinical and in vitro Data on the Antiviral
Activity of SNG001 at the 8(th) ESWI Influenza Conference
Southampton, UK - 6 December 2021: Synairgen plc (LSE: SNG), the
respiratory company developing SNG001, a formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta for
the treatment of severe viral lung infections, announced today an
oral presentation and a poster presentation at the 8(th) European
Scientific Working Group in Influenza (ESWI) Influenza Conference,
which is taking place virtually from 4-7 December 2021.
The oral presentation will highlight clinical data demonstrating
the antiviral activity of SNG001 in the lungs of patients with
asthma and those with chronic obstructive pulmonary disease
(COPD).
The poster presentation will highlight in vitro data showing the
antiviral activity of SNG001 against Alpha, Beta and Gamma
SARS-CoV-2 variants.
Details of the presentations are as follows:
Oral Presentation:
Title: Local delivery of interferon beta (SNG001) by inhalation
upregulates lung antiviral biomarkers
Presenter: Phillip D Monk, Ph.D., Chief Scientific Officer, Synairgen
Abstract: 270
Date/Time: 6 December 2021; 17:00-18:45 GMT
Track: Scientific Programme
Poster Presentation:
Title: Interferon beta has potent antiviral activity against
SARS-CoV-2 including variants of concern
Abstract: 269
Date/Time: On-demand
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No. 596/2014 ('MAR').
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Chief Financial Officer
Brooke Clarke, Head of Communications
Brooke.Clarke@synairgen.com
Tel: + 44 (0) 23 8051 2800
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
MKC STRATEGIES, LLC (US Media Relations)
Mary Conway
MConway@MKCStrategies.com
Tel: +1 516-606-6545
About Synairgen
Synairgen is a UK-based respiratory company focused on drug
discovery, development and commercialisation. The Company's primary
focus is developing SNG001 (inhaled interferon beta) for the
treatment of COVID-19 as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs. SNG001 has been granted Fast Track status from the US Food
and Drug Administration (FDA) and the Phase 3 SPRINTER trial was
deemed an Urgent Public Health study by the UK's National Institute
for Health Research (NIHR). Synairgen's Phase 3 clinical programme
is currently evaluating nebulised SNG001 in patients across 17
countries. In a Phase 2 trial in hospitalised COVID-19 patients,
SNG001 demonstrated a greater than two-fold chance of recovery to
'no limitation of activities' versus placebo.(1)
Founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com .
(1)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUVOURAWUURUA
(END) Dow Jones Newswires
December 06, 2021 02:00 ET (07:00 GMT)
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024